RecruitingPHASE1, PHASE2NCT04707300

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

Studying Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Assistance Publique - Hôpitaux de Paris
Principal Investigator
Olivier HERMINE, PhD & MD
Assistance Publique - Hôpitaux de Paris
Intervention
Human T Lymphoid Progenitor (HTLP) injection(drug)
Enrollment
10 target
Eligibility
18-66 years · All sexes
Timeline
20222028

Study locations (5)

Collaborators

URC-CIC Paris Descartes Necker Cochin

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04707300 on ClinicalTrials.gov

Other trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Additional recruiting or active studies for the same condition.

See all trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

← Back to all trials